Clinuvel Pharmaceuticals Limited Share Price
Stocks
CUV
AU000000CUV3
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Australian S.E.
11:40:08 29/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 8.380 AUD | +2.57% |
|
+1.58% | -32.74% |
| Market Cap | 42Cr 30Cr 26Cr 25Cr 22Cr 42Cr 2.83TCr 294.98Cr 113.68Cr 1.45TCr 110.86Cr 108.44Cr 4.64TCr | P/E 2027 * |
12.1x | P/E 2028 * | 11.6x |
|---|---|---|---|---|---|
| Enterprise Value | 14Cr 9.74Cr 8.59Cr 8.11Cr 7.36Cr 14Cr 934.85Cr 97Cr 38Cr 477.78Cr 37Cr 36Cr 1.53TCr | EV / Sales 2027 * |
1.47x | EV / Sales 2028 * | 1.05x |
| Free-Float |
83.79% | Yield 2027 * |
0.65% | Yield 2028 * | 0.73% |
| Markets | Quality | ||
|---|---|---|---|
Australian S.E.
| CUV | Delayed | |
Tradegate
| UR9 | Real-time | |
|
Boerse Muenchen
| UR9 | Real-time | |
|
OTC Markets
| CLVLF | Delayed | |
|
Berne S.E.
| UR9 | End-of-day quote | |
|
Deutsche Boerse AG
| UR9 | Delayed | |
|
Börse Stuttgart
| UR9 | Delayed |
Last Transcript: Clinuvel Pharmaceuticals Limited
| 1 day | +2.57% | ||
| 1 week | +1.58% | ||
| Current month | +4.49% | ||
| 1 month | -1.06% | ||
| 3 months | -16.12% | ||
| 6 months | -15.35% | ||
| Current year | -32.74% |
| 1 week | 7.95 |  | 8.42 |
| 1 month | 7.93 | | 8.64 |
| Current year | 7.93 | | 13.48 |
| 1 year | 7.93 | | 13.48 |
| 3 years | 7.93 | | 18.2 |
| 5 years | 7.93 | | 42.86 |
| 10 years | 5.9 | | 45.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 01/11/2005 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 30/06/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 29/01/2018 |
Susan Smith
BRD | Director/Board Member | - | 23/09/2019 |
| Chairman | - | 01/01/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 03/10/24 | Buy | Director | 8,333 | 0.0166% | ||
| 27/11/23 | Exercice | Chief Executive Officer | 3,01,125 | 0.6094% | ||
| 27/11/23 | Expiration | Chief Executive Officer | 15,13,750 | 3.0636% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.57% | +1.58% | -25.84% | -43.76% | 29Cr | |
| +3.13% | +17.65% | +730.79% | +102.91% | 7.88TCr | |
| -0.23% | -5.97% | +33.09% | -10.07% | 7.51TCr | |
| +0.21% | +2.24% | -6.14% | -27.67% | 6.11TCr | |
| -2.68% | -2.50% | +5.03% | +165.47% | 4.61TCr | |
| -1.07% | -1.21% | -9.92% | +32.27% | 4.76TCr | |
| -0.71% | +3.65% | +65.30% | -11.93% | 3.38TCr | |
| -1.30% | -1.16% | +48.97% | +110.20% | 2.53TCr | |
| -0.26% | -6.35% | +2.84% | +140.35% | 2.13TCr | |
| -0.64% | -1.58% | +60.16% | +95.78% | 1.54TCr | |
| Average | -0.10% | -0.45% | +90.43% | +55.36% | 4.05TCr | |
| Weighted average by Cap. | -0.01% | +0.45% | +157.76% | +53.50% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 9.49Cr 6.63Cr 5.84Cr 5.52Cr 5.01Cr 9.4Cr 636.09Cr 66Cr 26Cr 325.09Cr 25Cr 24Cr 1.04TCr | 10Cr 7.07Cr 6.23Cr 5.89Cr 5.34Cr 10Cr 678.67Cr 71Cr 27Cr 346.85Cr 27Cr 26Cr 1.11TCr |
| Net income | 3.51Cr 2.45Cr 2.16Cr 2.04Cr 1.85Cr 3.48Cr 235.35Cr 25Cr 9.44Cr 120.28Cr 9.21Cr 9.01Cr 385.7Cr | 3.67Cr 2.56Cr 2.26Cr 2.13Cr 1.93Cr 3.63Cr 245.81Cr 26Cr 9.86Cr 125.63Cr 9.62Cr 9.41Cr 402.84Cr |
| Net Debt | -28Cr -20Cr -17Cr -16Cr -15Cr -28Cr -1.9TCr -197.66Cr -76Cr -970.38Cr -74Cr -73Cr -3.11TCr | -32Cr -22Cr -19Cr -18Cr -17Cr -31Cr -2.12TCr -220.49Cr -85Cr -1.08TCr -83Cr -81Cr -3.47TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/26/29 | A$8.380 | +2.57% | 1,35,007 |
| 28/26/28 | A$8.170 | +1.87% | 91,901 |
| 25/26/25 | A$8.020 | -2.91% | 2,15,309 |
| 24/26/24 | A$8.260 | -0.24% | 1,50,282 |
| 23/26/23 | A$8.280 | +0.36% | 94,039 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
Select your edition
All financial news and data tailored to specific country editions
